Symbow Medical completed a $17 million Series A funding, led by China healthcare fund Huayi Capital. Symbow, a Beijing company, is developing a surgical navigation device that is designed to be used together with MRI or CT machines as a real-time navigator for surgery.

Unlike other surgical navigation devices, Symbow's device focuses on breast cancer diagnosis and minimally invasive surgery. The A round also included the state-owned National Emerging Industry Guidance Fund, Shandong Buchang Pharma and Sangel Capital.